PRECISION Trial Provides Added Guidance on NSAID Usage
NOVEMBER 14, 2016
Kevin R. Campbell, MD
For doctors concerned about cardiovascular disease in patients, there have been some lingering questions about the best medications to prescribe. A recent study looked particularly at patients either with coronary artery disease or those at risk of developing the conditon who could also suffer from other coronary events.
Kevin Campbell, MD, from the University of North Carolina at Chapel Hill School of Medicine, said the results of the PRECISION Trial, presented at the American Heart Association's Scientific Sessions (AHA 2016), can be pivotal in providing patient care going forward. Campbell said the results should assure providers that prescribing medications, like Celebrex, are safe for this patient population, though he also said more research should be done on the topic.